Processa Pharmaceuticals’ Post

#Article: After two decades of trial and error in #antibodydrugconjugates (#ADC) development, the field is poised to deliver a plethora of #targeteddrugs to treat a wide range of #tumor types. These are an emerging class of #highlypotent pharmaceutical drugs that are a combination of #immunotherapy and #chemotherapy. In ADCs, the most targeted #antigens are #ERBB2, #CD33, #CD19, #CD22, and #MSLN (mesothelin), and over 50 different known antigens have been used in ADCs as a target.1 But the important question here is: Do ADCs have the potential to be a game changer in revolutionizing cancer treatment? ADCs have been a promising class of targeted #cancertherapies for over 20 years, but their development has been challenged by several factors. One key challenge has been the complex nature of ADC design, which requires the combination of a cytotoxic drug, an antibody, a linker, and the conjugation technology that connects the components. Each of these components must be optimized in different ways depending on the cancer types or targets. It can take years to develop an ADC with the desired therapeutic profile.2 Despite these challenges, recent advancements in #ADCtechnology have renewed interest in this field. For example, the development of site-specific conjugation technologies has enabled the creation of more precise and stable ADCs, reducing off-target effects and increasing the concentration of the “magic bullet” available to reach tumor sites. In fact, there are a number of promising ADCs now in late-stage clinical trials, as well as plenty more in preclinical development. According to DataM Intelligence’s new analysis, the global ADC market size was valued at $5.0 billion in 2022 and is projected to witness lucrative growth by reaching $16.5 billion by 2030. The market is expected to exhibit a CAGR of 16.6% during the forecast period (2023–2030). Some of the major players operating in the ADC market include Takeda. @Hoffmann-La Roche, Pfizer, AstraZeneca, Gilead Sciences, Seagen, Astellas Pharma, Daiichi Sankyo, Inc. , GSK, and ADC Therapeutics. Read more from By Kriti K. and Manjari Palla, DataM Intelligence in @outsourcedpharma 👇🏼 https://lnkd.in/ecg-gmtM

The global Cancer Immunotherapy market was valued at US$ 49490 million in 2023 and is anticipated to reach US$ 172490 million by 2030 witnessing a CAGR of 20.0% during the forecast period 20242030. The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #CancerImmunotherapy #GlobalMarket #HealthcareIndustry #CancerTreatment #ImmuneSystem #MonoclonalAntibodies #ImmuneCheckpointInhibitors #CancerVaccines #Bioinformatics #Genomics

Check out the latest report from IMIR Market Research Pvt. Ltd. on the 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲𝘀 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Condition (Myeloma, Lymphoma, Breast Cancer, Others (Urothelial Cancer)), By Linker (Cleavable Linker, Non-cleavable Linker), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031. The antibody-drug conjugates (ADCs) contract manufacturing market is a vital segment within the pharmaceutical and biotechnology industries, supporting the development and production of innovative cancer therapeutics. ADCs combine the targeting capabilities of monoclonal antibodies with the cytotoxic properties of potent drugs, offering a promising approach for targeted cancer therapy. 📚 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗳𝗿𝗲𝗲 𝘀𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁:👇 https://lnkd.in/gy2CqEuu AbbVie, ADC Therapeutics, AstraZeneca, Aurigene Pharmaceutical Services Limited,. Axplora, BioTechnique, Boehringer Ingelheim, Cambrex, Catalent Pharma Solutions, Cerbios-Pharma SA, Corden Pharma - A Full-Service CDMO, Creative Biolabs, Daiichi Sankyo US, EirGenix, Inc., GBI Bio, Gilead Sciences, GSK, GTP Bioways, Iksuda Therapeutics, ImmunoGen, Inc., LCB Group, Lonza, MabPlex International Co., Ltd., Merck KGaA, Darmstadt, Germany, Mersana Therapeutics, MicroBiopharm Japan Co., Ltd., Novasep, Pantheon, Pfizer, Pierre Fabre Group, Piramal Group, Piramal Pharma Solutions, Recipharm, Regeneron Pharmaceuticals, Inc., Samsung Biologics, Sanofi, Sartorius

[Clinical Trials] 「Ionis Pharmaceuticals, Inc. Pharmaceuticals reports phase 3 OASIS-HAE and OASISplus studies show reduction in monthly attack rates for hereditary angioedema with donidalorsen」 「Novartis' phase III ASC4FIRST trial reveals Scemblix achieves higher MMR rates than standard-of-care tyrosine kinase inhibitors in chronic myeloid leukemia」 [Deals] 「Adaptimmune and Galapagos partner to evaluate MAGE-A4 TCR therapy uza-cel in head & neck cancer using a decentralized manufacturing platform」 [Regulatory] 「Takeda's recombinant ADAMTS13 recommended by EMA's CHMP for ADAMTS13 deficiency treatment in cTTP patients, awaits European Commission decision」 「CHMP recommends approval of risankizumab for adults with moderately to severely active ulcerative colitis based on Phase 3 trial results」 「FDA sets PDUFA date for Iterum Therapeutics plc Therapeutics' Resubmitted NDA of Oral Sulopenem After REASSURE Trial Results in Uncomplicated Urinary Tract Infections」 「European Commission approves Biogen's QALSODY for treatment of ALS with SOD1 gene mutation」 View the full newsletter contents for free via the link in the comments.

Day One Biopharmaceuticals has made an exclusive licensing agreement with MabCare for $55M upfront, to develop, manufacture, and commercialize MTX-13 (DAY301) worldwide, excluding greater China. DAD301, a novel ADC with potential to be FIC, targeting protein-tyrosine kinase 7 (PTK7), received IND clearance from the FDA in April 2024. PTK7 is a clinically proven target that is overexpressed in multiple adult cancers but has with limited expression in normal tissues or organs, making it an attractive target for therapeutic development. By the way, Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Our society’s official journal, Antibody Therapeutics (2023 CiteScore: 8.7) is an international peer-reviewed, open access journal published by Oxford University Press. You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal. https://lnkd.in/gsTu_U2 #antibodydrugconjugate #ADC #Oncology #Antibodies #mabs #FIC https://lnkd.in/etd4mvic

🚨Predicine 𝐬𝐞𝐞𝐤𝐬 𝐭𝐨 𝐩𝐞𝐧𝐞𝐭𝐫𝐚𝐭𝐞 𝐭𝐡𝐞 𝐔𝐒 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 (𝐂𝐃𝐱) 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐢𝐭𝐡𝐢𝐧 𝐚 𝐭𝐢𝐦𝐞𝐟𝐫𝐚𝐦𝐞 𝐨𝐟 𝐣𝐮𝐬𝐭 𝐭𝐡𝐫𝐞𝐞 𝐲𝐞𝐚𝐫𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 𝐰𝐢𝐭𝐡 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬🚨... 🤝🏻Predicine recently partnered with The Janssen Pharmaceutical Companies of Johnson & Johnson for companion diagnostics development, adding them to a 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐥𝐢𝐬𝐭 𝐨𝐟 𝐩𝐡𝐚𝐫𝐦𝐚 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐬. 🧪𝐓𝐡𝐞 𝐇𝐚𝐲𝐰𝐚𝐫𝐝-𝐛𝐚𝐬𝐞𝐝 𝐜𝐨𝐦𝐩𝐚𝐧𝐲 aims to commercialize its DNA and RNA #ngs assays, with 𝐡𝐨𝐩𝐞𝐬 𝐨𝐟 FDA 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐫𝐞𝐞 𝐭𝐨 𝐟𝐢𝐯𝐞 𝐲𝐞𝐚𝐫𝐬. While focusing on clinical trials and #companiondiagnostics, Predicine plans to offer FDA-approved tests for patient testing. 🥼Founder and #CEO Shidong Jia 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐬 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥𝐢𝐳𝐢𝐧𝐠 𝐭𝐡𝐞𝐢𝐫 𝐏𝐫𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐂𝐚𝐫𝐞 𝐚𝐬𝐬𝐚𝐲 𝐬𝐨𝐨𝐧, with agreements in place for bladder and lung cancer #diagnostics . 🚀Predicine's recent partnerships include Johnson & Johnson, AstraZeneca, Roche, and others. 𝐏𝐫𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐂𝐚𝐫𝐞 has received CE-IVD marking and FDA breakthrough device designation. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐲 𝐢𝐬 𝐚𝐥𝐬𝐨 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐢𝐧𝐠 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐟𝐨𝐫 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲. 🧬Predicine's 𝐚𝐬𝐬𝐚𝐲𝐬 𝐝𝐞𝐭𝐞𝐜𝐭 𝐯𝐚𝐫𝐢𝐨𝐮𝐬 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 relevant for #oncology , including minimal residual disease. 💬𝐉𝐢𝐚 𝐬𝐚𝐢𝐝 the company has been focusing its efforts on unmet needs in cancer testing, stating: "𝑾𝒉𝒆𝒏𝒆𝒗𝒆𝒓 𝒘𝒆 𝒅𝒆𝒔𝒊𝒈𝒏 𝒐𝒖𝒓 𝒂𝒔𝒔𝒂𝒚𝒔, 𝒊𝒕'𝒔 𝒂𝒍𝒘𝒂𝒚𝒔 𝒃𝒆𝒄𝒂𝒖𝒔𝒆 𝒕𝒉𝒆𝒓𝒆'𝒔 𝒏𝒐 𝒃𝒆𝒕𝒕𝒆𝒓 𝒔𝒐𝒍𝒖𝒕𝒊𝒐𝒏"! 🌐Check them out here: https://www.predicine.com/ #IVD 🔗Source: https://lnkd.in/eB4tZfiX

As per DelveInsight analysis, the total Multiple Myeloma market size in the 7MM was estimated to be nearly USD 20 billion in 2022, which is expected to show positive growth by 2032. The Multiple Myeloma treatment landscape has witnessed remarkable evolution in recent years, offering new hope to patients battling this complex hematologic malignancy. Currently, pharma and biotech giants, such as The Janssen Pharmaceutical Companies of Johnson & Johnson, Gracell Biotechnologies, Regeneron, Pfizer, IASO BioTherapeutics（驯鹿生物）Novartis, Legend Biotech, among others, are actively working in the Multiple Myeloma therapeutics market to further improve the treatment dynamics. Get more detailed insights into the evolving therapeutics market: https://lnkd.in/dBn2EKrP #healthcarejob #biotechnology #lifesciences #pharmaceutical #market #marketforecast #marketanalysis #clinicaltrials #clinicalresearch #fda #healthcaremarket #healthcareindustry #marketoutlook #multiplemyeloma

CG Oncology (Nasdaq: CGON) Market Capitalization - $2.09B Share price - $31.32   Recommendation: Buy.  Time horizon: Hold the stock for several years CG Oncology is a clinical biopharmaceutical company focused on developing and commercializing therapeutics for patients afflicted with bladder cancer. The lead product cretostimogene is a conditionally replicating oncolytic serotype 5 adenovirus designed to replicate in and kill cancer cells. Cretostimogene is in clincal trials to treat non-muscle invasive bladder cancer (NMIBC). Clinical trials BOND-003   Phase 3       Cretostimogene monotherapy      BCG Unresponsive, High risk NMIBC PIVOT-006   Phase 3       Cretostimogene monotherapy      Intermediate risk NMIBC CORE-001   Phase 2       Cretostimogene+Pembrolizumab  BCG Unresponsive, High risk NMIBC In June, 2024 CGON reported CORE-001 results that mentioned the CR rate in the intention to treat population at 12 months was 57%, and at 24 months was 54%. The PFS was 100%. TRAEs were not significant. The CR rate low drop from 12 months to 24 months compares favorably to competitor drugs that include: Anktiva (FDA approved April, 2024), Adstiladrin (FDA approved December, 2023) and Keytruda (FDA approved January, 2020). Johnson & Johnson’s TAR-200 (in P2) comparable figures are not available. CGON Financials Cash and cash equivalents $566M     as of March 31, 2024 Net cash used in operations   ($26,012) three months ended March 31, 2024 Collaborations Lepu Biotech – mainland China including Hong Kong and Macau Regulatory milestones up to $2.5M Commercial milestones up to $57.5M. High single digit percentage royalty. Kissei Pharmaceutical – southeast Asia. Regulatory milestones up to $33M. Commercial milestones up to $67M Mid-twenties percentage royalty * CGON will pay Kissei a royalty of a low single digit percentage on net sales outside the Kissei Territory, and outside of the Lepu Territory. Market size Growth Plus Market Reports believes that the global non muscle invasive bladder cancer market was $2.9B in 2022. They expect a CAGR of 6.5% over the next decade. Buy 2031 the market will have a value in excess of $5B.

Pharma Pulse: Breaking News and Updates FDA Expands GSK’s Jemperli Approval for Endometrial Cancer. Biogen to Acquire Reata Pharmaceuticals, Inc.. AstraZeneca and Daiichi Sankyo, Inc.'s Enhertu Shows Survival Boost in HER2+ Solid Tumors. FDA Rejects Citius’ Revived IL-2 Therapy for Lymphoma. FDA Grants Fast Track Designation to IVS-3001 (Invectys) for the Treatment of Renal Cell Carcinoma. Biohaven’s Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy (SMA). Get a more detailed analysis: https://lnkd.in/dQjK4fN2 #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch

Mabwell Therapeutics' Pioneering Esophageal Cancer Therapy Earns FDA Orphan Drug Status Thriving in pharmaceutical innovation, Mabwell Therapeutics has secured an Orphan Drug Designation for their groundbreaking Nectin-4-targeting ADC therapy, 9MW2821, by the FDA. This milestone recognises its potential in treating the less common, yet aggressive, esophageal cancer. Orphan Drug status is a boon for rare disease treatment developers, offering a package of benefits like trial cost tax credits and a significant seven-year exclusive market presence post-approval. For Mabwell, this accolade builds on the Fast Track Designation bestowed earlier by the FDA, accentuating the drug's promise in advanced esophageal cancer care. #MabwellTherapeutics #OrphanDrugDesignation #HealthcareInnovation